Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 120

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9B
Chunk 120
---
 options during the year ended December 31, 2024, are as follows:

 Schedule
of key assumptions used to value stock options

    Expected volatility 
     88.8%-90.4% 
  
    Risk-free interest rate 
     3.7%
  
    Exercise price 
    $5.02 
  
    Expected term (in years) 
     5.1
                                            to 5.62 years 
  
    Dividend yield 
     - 

    F-15

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and  2023

Note
7 – Income Taxes

The
significant components of the Company’s net deferred tax assets are as follows as of December 31:

Schedule of net
deferred tax assets

    2024  
    2023 

    December
    31, 

    2024  
    2023 
  
    Deferred tax assets 

    Net operating
    loss carry-forward 
    $4,427,679  
    $288,379 
  
    Section 174 Qualified Research
    Expenditures 
     995,500  
     526,248 
  
    Stock Compensation 
     1,680,019  
     - 
  
    R&D Credit 
     51,278  
     - 
  
    Other 
     28,007  
     31,724 
  
    Deferred tax assets, gross 
     7,182,483  
     846,351 
  
    Less:
    valuation allowance 
     (7,182,483) 
     (846,351)
  
    Deferred tax assets, net 
     -  
     - 
  
    Deferred tax liabilities 

    Total
    net deferred tax asset 
    $-  
    $- 

Beginning
in 2022, in accordance with Internal Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized
over a period of five years. Accordingly, for income tax purposes, and as of December 31, 2024 and December 31, 2023, the Company has
recorded a deferred tax asset totaling approximately $1.0 million and $0.5 million, respectively, related to the timing difference between
GAAP and Tax recognition of these expenditures